PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 5, 2004, Pages 720-724

  Smyczek Gargya, Brigitte ^a   Fersis, Nikos ^a   Dittmann, Helmut ^a   Vogel, Ulrich ^a   Reischl, Gerald ^a   Machulla, Hans Juergen ^a   Wallwiener, Diethelm ^a   Bares, Roland ^a   Dohmen, Bernhard M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Breast cancer; FDG PET; FLT PET; Imaging

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROTHYMIDINE F 18; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IMAGE QUALITY; INFLAMMATION; LYMPH NODE METASTASIS; MEDIASTINUM; METASTASIS; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TWINS;

ADULT; AGED; BREAST NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PILOT PROJECTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 2442566549     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1462-8     Document Type: Article

References (11)

1. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2:157-164.
2. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, LawhornCrews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 1998; 4:1334-1336.
3. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43:1210-1217.
4. Buck AK, Schirrmeister H, Hetzel M, von der Heide M, Halter G, Glatting G, Mattfeldt T, Liewald F, Reske SN, Neumaier B. 3-deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334.
5. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallieres E, Wood DE. In vivo validation of 3′deoxy-3′ -[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-3323.
6. Dohmen BM, Kuntzsch M, Dittmann H, Wei R, Eschmann SM, Machulla H-J, Bares R. FLT-Metabolismus beim Menschen: Konsequenzen für die [F-18]FLT-PET. Nuklearmedizin 2001; 39:V19.
7. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ, Bares R. [(18)F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30:1407-1412.
8. Lu I, Samuelsson L, Bergstrom M, Sato M, Fasth KJ, Langstrom B. Rat studies comparing 11C-FMAU, 18-FLT, and 76Br-BFU as proliferation marker. J Nucl Med 2002; 43:1688-1698.
9. Grierson JR, Vesselle H, Hofstrand P, Chin L, Rasey JS. Comparative uptake and cell cycle measurements with [F-18]FLT vs [H-3]thymidine in mammalian tumor cells. J Nucl Med 1998; 39:229P-230P.
10. Morabito A, Magnani E, Gion M, Sarmiento R, Capaccetti B, Longo R, Gattuso D, Gasparini G. Prognostic and predictive indicators in operable breast cancer. Clin Breast Cancer 2003; 3:381-390.
11. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, Von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1 N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9:923-930.